APA (7th ed.) Citation

K, S., H, M., T, G., C, C., P, R., & S, C. (2023). Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE). Multiple sclerosis (Houndmills, Basingstoke, England), 29(8), 956. https://doi.org/10.1177/13524585231175284

Chicago Style (17th ed.) Citation

K, Smoot, Marginean H, Gervasi-Follmar T, Chen C, Repovic P, and Cohan S. "Evaluating the Efficacy and Safety of Transitioning Patients with Multiple Sclerosis from Natalizumab to Ocrelizumab (OCTAVE)." Multiple Sclerosis (Houndmills, Basingstoke, England) 29, no. 8 (2023): 956. https://doi.org/10.1177/13524585231175284.

MLA (9th ed.) Citation

K, Smoot, et al. "Evaluating the Efficacy and Safety of Transitioning Patients with Multiple Sclerosis from Natalizumab to Ocrelizumab (OCTAVE)." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 29, no. 8, 2023, p. 956, https://doi.org/10.1177/13524585231175284.